Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New Vision for Medical Device Industry to Call For Fusion of Drugs and Devices
October 8, 2007
- NEW PRODUCTS／GSK, Taisho to Launch Japan's First OTC Drug for Labial Herpes
October 8, 2007
- GENERICS NEWS IN BRIEF
October 8, 2007
- DBV Tech. to Enter Japanese Market with Viaskin Technology
October 8, 2007
- R&D NEWS IN BRIEF
October 8, 2007
- NEW PRODUCTS／Kyowa Hakko Kogyo: Topina Tablets for Partial Seizures
October 8, 2007
- Korosho Calls on Major Domestic Drug Makers to Develop Vaccines
October 8, 2007
- Global Sales of Prevenar to Top US$3 Bil. in 2009: Mr Larsen of Wyeth
October 8, 2007
- Nagoya Lab. to Continue to Operate as a New Company: Pfizer Japan
October 8, 2007
- Kyorin Pharm. to Merge with Nisshin Kyorin Pharm.
October 8, 2007
- Roche to Pursue Alliances to Strengthen R&D in 5 Fields
October 8, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 8, 2007
- REGULATORY NEWS IN BRIEF
October 8, 2007
- Tanabe Licenses Bepotastine Besilate to ISTA Pharm.
October 8, 2007
- JMA Does Not Support NHI Pricing System Proposed by Industry
October 8, 2007
- JT, Torii License New Drug for Hyperphosphatemia from Keryx
October 8, 2007
- GSK Applies for Cervical Cancer Vaccine
October 8, 2007
- Wyeth Applies for the Pneumococcus Vaccine Prevenar
October 8, 2007
- Yasuo Fukuda Elected Prime Minister
October 8, 2007
- JSMD Issues Official Statement on Risk of Suicide due to Antidepressants
October 1, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…